Fetotoxicity of NSAIDS and RAAS-inhibitors in the 2nd and 3rd trimester of pregnancy (paediatric-nephrologic approach)

• Conditions: I10; Q61.4; Q60; Essential (primary) hypertension; Renal dysplasia; Renal agenesis and other reduction defects of kidney

• Registration Number: DRKS00011861
• Lead Sponsor: Pharmakovigilanzzentrum Embryonaltoxikologie Charité-Universitätsmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-31
• Study Completion: 2020-07-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 287

Inclusion Criteria

Patients who had an apointment in the pediatric clinic for nephrology in the years 2015 and 2016.

Exclusion Criteria

none

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Are renal hypoplasia or renal dysplasia or hypertension in children and adolescents more frequent when the mother has taken an NSAID, metamizole or RAAS-inhibitor in the second half of pregnancy? For this purpose, all patients who were seen in the Charité clinic for pediatric nephrology in the past two years will be contacted by questionnaire.

Secondary Outcome Measures

Name	Time	Method
Are there any signs of a minimum exposure time and/or a minimum dose? For this purpose, all patients who were seen in the Charité clinic for pediatric nephrology in the past two years will be contacted by questionnaire.